Expert Insights

At the 2023 ASCO Annual Meeting in Chicago, Illinois, Kerry Anne Rogers, MD, provided insights into real-world dosing ibrutinib patterns and outcomes among patients with chronic lymphocytic leukemia.

At the 2023 ASCO Annual Meeting, Omid Hamid, MD, shares results from a trial examining the combination treatment of fianlimab plus cemiplimab for patients with advanced melanoma.

Javier Cortes, MD, PhD, discusses results from the PHERGain study, evaluating chemotherapy de-escalation strategies in HER2-positive early breast cancer, presented at the 2023 ASCO Annual Meeting.

At the 2023 ASCO annual meeting, Swetha Kambhampati, MD, provided insights into the real-world outcomes of brexucabtagene autoleucel therapy for patients with relapsed/refractory MCL through a subgroup analysis of outcomes by prior treatment.

Debra Richardson, MD, discusses results from a real-world analysis exploring the effectiveness of PARP inhibitor maintenance therapy in patients with advanced ovarian cancer, specifically defined by biomarker status.

At the 2023 ASCO annual meeting, Emily C. Liang, MD, shared data on the long-term outcomes of patients with relapsed/refractory chronic lymphocytic leukemia treated with CD19-targeting CAR T-cell therapy.

Claire Harrison, MD, presents results from the phase 2 MAGIC-PV trial, which indicate that ruxolitinib treatment yielded superior event-free survival and complete responses vs best available therapy for patients with...

At the 2023 ASCO Annual Meeting, Roy Herbst, MD, PhD, shared results from the overall survival analysis of the phase 3 ADAURA trial, evaluating adjuvant osimertinib for patients with resected EGFR-mutated non-small cell lung cancer.

At the 2023 ASCO Annual Meeting, Valerie Crolley, MBBS, MRCP, discusses potentially targetable mutations among patients with intrahepatic cholangiocarcinoma from the BILCAP trial.

Lorenzo Falchi, MD presents updated EPCORE NHL-2 data on epcoritamab combined with R-CHOP for the treatment of patients with high-risk diffuse large B-cell lymphoma.